Digital Pathway: Challenges and Advances in the Diagnosis and Management of Immune Thrombocytopenic Purpura
Immune thrombocytopenic purpura (ITP) is an autoimmune bleeding disorder that is characterized by suboptimal platelet count, purpura and hemorrhage. The burden of ITP is significant, leading to considerable mortality and life-threatening events such as intracranial hemorrhage and septicemia, if untreated, as well as reduction in health-related quality of life.
Despite these impacts and an increase in the understanding of the pathophysiology of ITP, the approaches for the initial screening, diagnosis, and management vary significantly, leading to diagnostic and treatment delays, and ultimately increased risk for adverse events . Significant developments have been made recently in the diagnosis and management of ITP, and in this activity, experts will walk you through these advances in order to increase awareness about ITP and aid you in improving the care for these patients. This design of this activity ensures that these topics are presented in a format that is easy to follow, containing a mix of videos & resources, organized into different segments to facilitate learning.
This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), registered nurses, nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, dieticians, and other allied health professionals.
After completing this activity, the participant should be better able to:
- Outline the pathophysiology, clinical presentation, and the screening and diagnosis of ITP.
- Summarize the efficacy and safety of conventional and newer ITP treatment options.
- Develop individualized treatment regimens for ITP based on current evidence, available treatment options, and patient preferences.
- Discuss the rationale, efficacy, and safety of emerging treatment options for refractory ITP.
- Recognize the impacts of COVID-19 on ITP presentation and management, and review therapy accordingly in ITP patients with or at-risk for COVID-19.
Hanny Al-Samkari, MD
Classical Hematologist and Clinical Investigator
Co-Director, Hereditary Hemorrhagic Telangiectasia Center
Massachusetts General Hospital
Assistant Professor of Medicine
Harvard Medical School
Dr. Al-Samkari discloses the following:
Consulting Fees: Agios, Forma, argenx, Rigel, Moderna, Novartis, Dova/Sobi
Contracted Research: Agios, Dova/Sobi, Amgen
Cindy Neunert, MD, MSCS
Section Head, Pediatric Hematology
Columbia University Medical Center
Dr. Neunert has nothing to disclose.
Michele P. Lambert, MD, MSTR
Associate Clinical Director, Frontier Program in Immune Dysregulation
Director, Clinical Coagulation Laboratory
Medical Director, Special Coagulation Laboratory
Associate Professor of Pediatrics
Children’s Hospital of Philadelphia
Dr. Lambert discloses the following:
Grant/Research Support: AstraZenca, Sysmex, Novartis, Argenx, Principia, Dova/Sobi, Janssen, Octapharma, Rocket Pharma
Speakers Bureau/Honoraria for Non-CME: Novartis
Consultant/Advisory Board: Novartis, Argenx, Principia, Octapharma, Dova, Novartis, Sysmex, Janssen, Sobi, Shionogi
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
This activity is supported by educational funding provided by Amgen.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Medical Education (TME). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is a knowledge-based activity. Universal Activity Numbers (UAN): JA4008162-9999-22-352-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The TME planners and others have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period September 19, 2022 through September 18, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.